



저작자표시-비영리-변경금지 2.0 대한민국

이용자는 아래의 조건을 따르는 경우에 한하여 자유롭게

- 이 저작물을 복제, 배포, 전송, 전시, 공연 및 방송할 수 있습니다.

다음과 같은 조건을 따라야 합니다:



저작자표시. 귀하는 원저작자를 표시하여야 합니다.



비영리. 귀하는 이 저작물을 영리 목적으로 이용할 수 없습니다.



변경금지. 귀하는 이 저작물을 개작, 변형 또는 가공할 수 없습니다.

- 귀하는, 이 저작물의 재이용이나 배포의 경우, 이 저작물에 적용된 이용허락조건을 명확하게 나타내어야 합니다.
- 저작권자로부터 별도의 허가를 받으면 이러한 조건들은 적용되지 않습니다.

저작권법에 따른 이용자의 권리는 위의 내용에 의하여 영향을 받지 않습니다.

이것은 [이용허락규약\(Legal Code\)](#)을 이해하기 쉽게 요약한 것입니다.

[Disclaimer](#)

의학과 석사 학위논문

췌장암으로 절제를 받은 환자에서  
수술 후 근육량 보존이  
생존에 미치는 영향

**Postoperative Muscle Mass Restoration  
as a Prognostic Factor  
in Patients with Resected Pancreatic Cancer**

2020년 8월

서울대학교 대학원  
의학과 중개의학 전공  
이종찬

## **Abstract**

# **Postoperative Muscle Mass Restoration as a Prognostic Factor in Patients with Resected Pancreatic Cancer**

**Jongchan Lee**

**Department of Medicine, Translational Medicine Major  
Graduate School (Master Course), Seoul National University**

**Background:** Recent studies have found that muscle depletion may be a prognostic predictor in patients with pancreatic cancer (PC). However, in these studies, limited data were used to assess the relationship between the serial change in body composition and outcomes after pancreatectomy. Hence, the changes in body composition were evaluated during the perioperative period in patients with PC and their association with the overall survival (OS).

**Methods:** A total of 89 patients with PC who received surgery with curative intent between 2006 and 2015 were included in this study. These patients underwent serial

computed tomography (CT) scans: preoperatively, immediately after surgery (4 weeks), and 12 and 24 weeks after resection. The muscle and visceral fat areas were measured at the third lumbar vertebra level on cross-sectional CT images using sliceOmatic V5.0 program (TomoVision, Canada). The body composition ratio was determined by dividing the post-resection body composition at each point (4, 12, and 24 weeks) by the pre-resection body composition. Patients were divided into two groups — higher and lower groups — based on this body composition ratio (skeletal muscle mass ratio [SMR], visceral fat mass ratio [VFR]). The OS was compared between the two groups using the log-rank test.

**Results:** The median age of patients was 63 (27–84) years, and the baseline body mass index was 23.0 (17.0–35.8) kg/m<sup>2</sup>. In the comparison of the SMR, there was no significant difference in the OS between the two groups at 4 and 12 weeks (4 weeks,  $P = 0.488$ ; 12 weeks,  $P = 0.397$ ). However, the higher group showed a longer OS than the lower group at 24 weeks (39 vs. 20 months,  $P = 0.008$ ). Similarly, in the VFR, there was no significant difference in the OS between the two groups at 4 and 12 weeks (4 weeks,  $P = 0.732$ ; 12 weeks,  $P = 0.060$ ). However, the OS was longer in the higher group at 24 weeks (35 vs. 22 months,  $P = 0.023$ ). When the effect of muscle restoration at 24 weeks after resection on the OS was analyzed by gender, there was no significant difference between the OS and SMR in the male group ( $P = 0.213$ ), but a significant difference was noted in the female group ( $P = 0.002$ ). In the multivariate Cox regression analysis, the SMR at 24 weeks after resection was significantly associated with the OS ( $P = 0.023$ ) but not VFR at 24

weeks. In 69 patients without recurrence at 6 months, the SMR at 24 weeks was related to longer OS but without statistical significance ( $P = 0.07$ ).

**Conclusions:** This study suggests that the restoration of muscle mass at 24 weeks after resection may be an independent prognostic factor for survival in patients with resected PC.

.....

**Keywords:** Skeletal muscle mass, Visceral fat mass, Sarcopenia, Resected pancreatic cancer, Changes in body composition

**Student Number:** 2017-23421

# Contents

<b>Introduction</b> .....	<b>1</b>
<b>Materials and Methods</b> .....	<b>3</b>
<b>Study patients</b> .....	<b>3</b>
<b>Body composition measurements and definition of the changes in     body composition</b> .....	<b>4</b>
<b>Statistical analysis</b> .....	<b>5</b>
<b>Results</b> .....	<b>6</b>
<b>Patient characteristics</b> .....	<b>6</b>
<b>Changes in body composition parameters</b> .....	<b>6</b>
<b>Survival according to the body composition ratio</b> .....	<b>7</b>
<b>Survival in patients without early recurrence</b> .....	<b>8</b>
<b>Discussion</b> .....	<b>9</b>
<b>Conclusion</b> .....	<b>12</b>
<b>References</b> .....	<b>13</b>
<b>Figures</b> .....	<b>19</b>
<b>Tables</b> .....	<b>24</b>

## **Introduction**

Pancreatic cancer (PC) is one of the leading causes of cancer-related mortality worldwide [1]. Despite much advancement in the treatment of PC, the prognosis remains poor. Adjuvant chemotherapy after surgical resection has been reported to improve the postoperative prognosis in patients with PC [2,3]. Nonetheless, several patients still develop recurrence after curative resection [4,5]. Therefore, several studies are underway to investigate the potential factors influencing the prognosis of PC after resection [6,7].

Sarcopenia is a condition that is characterized by the loss of muscle mass, strength, and function [8,9]. Decreased muscle mass results in functional impairment, such as falls and loss of autonomy [10]. Several mechanisms are involved in the development of sarcopenia: age, endocrine, muscle disuse, inadequate nutrition, neurodegenerative disease, and cachexia [11]. Sarcopenia is increasingly recognized as an important issue even in cancer management. Most patients with cancer are exposed to several factors that cause muscle mass to decrease and muscle dysfunction, including malnutrition, physical inactivity, tumor-derived factors, and cancer therapy [12].

Several studies have been conducted to evaluate how the change in body composition influences the prognosis of patients with lung, esophageal, and colorectal cancers [13-15]; to our knowledge, such studies are currently underway for patients with PC [16-18]. PC is associated more with weight loss than other

cancers because it can cause diabetes mellitus, gastrointestinal obstruction, and secretory disorders of digestive enzymes. Sarcopenia, sarcopenic obesity, and a decrease in muscle density on computed tomography (CT) at the time of diagnosis have been found to be associated with poor prognosis [6,16,19]. Moreover, a recent study has shown that a decrease in the skeletal muscle in patients with inoperable locally advanced PC is associated with poorer prognosis [20].

However, to date, there are only a few studies investigating the association between serial body composition change and prognosis over time in patients with resected PC. Hence, the purpose of this study was to investigate the trajectory of body composition after PC resection and the relationship between body composition change and overall survival (OS).



# **Materials and Methods**

## **Study patients**

A total of 326 patients with PC who received resection at Seoul National University Bundang Hospital between January 2006 and December 2015 were reviewed. Among these, those who underwent surgery for palliation or received neoadjuvant chemotherapy were excluded. Patients without follow-up CT scans available on a regular basis for up to 6 months after surgery were also excluded. Finally, 89 patients with PC were enrolled. Follow-up duration was from 6.4 to 146.9 months.

CT was performed at the time of diagnosis, immediately after resection (4 weeks), and at approximately 12 and 24 weeks after resection. CT scans using a pancreatic protocol were obtained to investigate any complications immediately after resection and again at 12 and 24 weeks after resection to assess possible recurrence or progression of the disease.

The medical records of all participants were collected and anonymized, and this study was approved by the institutional review board (IRB) of Seoul National University Bundang Hospital (Seongnam, Republic of Korea) (B-1912-585-104). Since this study was a retrospective analysis of clinical data, consent requirement was waived by the local IRB.

## **Body composition measurements and definition of the changes in body composition**

Images of the cross-sectional areas of the skeletal muscle mass (SMM) and visceral fat mass (VFM) at the midpoint of the third lumbar vertebral body (L3) were obtained via a CT scan. The cross-sectional image of the L3 level contained the psoas, erector spinae, quadratus lumborum, transversus abdominis, external and internal oblique muscles, and rectus abdominis. These body compositions were analyzed using the sliceOmatic V5.0 software (TomoVision, Magog, Canada). In brief, sliceOmatic is a program that makes it possible to distinguish specific tissues using the Hounsfield unit (HU) thresholds. The skeletal muscles were quantified between the HU range of -29 to 150 HU and the visceral adipose tissue using the range of -150 to -50 HU. This program summed the pixels of the area of each tissue and expressed it as a number. The boundary of the tissue was calibrated manually as needed. To prevent disagreement between the observers, one well-trained observer analyzed all 356 CT images using this program.

To determine the changes in the body composition during the follow-up period, the body composition ratio at each time point (4, 12 and 24 weeks after resection) to the body composition at the time of diagnosis was calculated: the skeletal muscle mass ratio (SMR) and visceral fat mass ratio (VFR). Then, the median values of SMR and VFR at each time point were obtained. Based on this, patients were divided into one of two groups at each time point: lower and higher group. Then the

OS of two groups according to the body composition ratio was compared.

## **Statistical analysis**

The patients' baseline characteristics and body composition were presented as the mean and standard deviation for continuous variables and proportions and percentages for categorical variables. The survival time was defined as the time from diagnosis to death, and the median OS was determined by the Kaplan–Meier method. A comparison of survival of subgroups was performed using the log-rank test. The Cox proportional hazards regression model was used to determine the relationship between the variables and survival as hazard ratios (HR) and 95% confidence intervals (CI). The results with two-sided t-test and a value of  $P < 0.05$  were considered to indicate statistical significance. Statistical analyses were performed using the STATA version 14.0 (StataCorp, College Station, TX, USA).

## **Results**

### **Patient characteristics**

This study included 89 patients with resected PC with four serial CTs before resection and 4, 12, and 24 weeks after resection. Their demographics and clinical characteristics are shown in Table 1. The median age was 63 years (range, 27–84 years), and 55 of 89 patients (61.8%) were men. The median body mass index (BMI) was 23.0 kg/m<sup>2</sup> (range, 17.0–35.8 kg/m<sup>2</sup>). Thirty-eight patients (42.7%) had a history of preoperative diabetes mellitus. Approximately two-thirds of patients (69.7%) underwent pylorus-preserving pancreaticoduodenectomy (PPPD) or standard pancreaticoduodenectomy (PD), and the remainder underwent distal pancreatectomy (DP). R0 resection was achieved in 67 (75.3%) patients, and 57 (64.0%) patients received more than four cycles of effective adjuvant chemotherapy.

### **Changes in body composition parameters**

The change of trajectory of body compositions, such as BMI, SMM, and VFM were investigated (Table 2). The overall observation showed that the BMI, SMM, and VFM decreased after PC resection throughout the 12-week period after resection, regardless of gender. In men, the SMR and VFR decreased throughout the 24-week period after resection although the degree of reduction was lower. In women, however, the skeletal muscle and visceral fat reached nadir at 12 weeks, which then

slightly recovered at 24 weeks (Table 2).

When the correlation between the body composition changes and operation methods (PPPD vs. PD vs. DP), as well as the correlation between body composition changes and diabetes mellitus were analyzed, there were no significant differences in the changes in the SMR and VFR (data not shown).

### **Survival according to the body composition ratio**

The median follow-up duration was 26.9 months after resection. The relationship between the OS and BMI as well as between the SMM and VFM before resection were examined. The Kaplan–Meier analysis found no significant difference in the OS according to the BMI ( $P = 0.311$ ), SMM ( $P = 0.234$ ), and VFM ( $P = 0.667$ ) before resection (Fig. 1).

When the SMR was analyzed at each time point, there was no significant difference in the median OS between the higher and lower groups at 4 ( $P = 0.488$ ) and 12 ( $P = 0.397$ ) weeks after resection. However, the higher group showed a longer median OS than the lower group at 24 weeks (39 vs. 20 months,  $P = 0.008$ ) (Fig. 2). Similarly, when the VFR was analyzed, the OS did not differ significantly between the higher and lower groups at 4 ( $P = 0.732$ ) and 12 ( $P = 0.060$ ) weeks after resection. However, the OS was longer in the higher visceral fat group at 24 weeks (35 vs. 22 months,  $P = 0.023$ ) (Fig. 3). The baseline characteristics of the higher and lower groups at 24 weeks were analyzed and these are presented in table

3.

Patients were divided based on gender, and the effect of the restoration of SMM at 24 weeks after resection on the OS was analyzed using the Kaplan–Meier method. According to this analysis, the difference between SMR and OS was not significant in the male group ( $P = 0.213$ ) but was significant in the female group ( $P = 0.002$ ) (Fig. 4).

A univariate analysis of prognostic factors for the OS was performed on several variables, including gender, age, adjuvant chemotherapy, low VFR, and low SMR. Low VFR and SMR means patients whose ratio of visceral fat and skeletal muscle of the third lumbar area at 24 weeks point after resection to the visceral fat and skeletal muscle at the third lumbar area on pre-resection point is lower than the median value. As a result, low SMR and low VFR were found to be significant prognostic factors. However, in the multivariate Cox regression analysis, only the SMR at 24 weeks ( $P = 0.023$ ) was significantly associated with the OS, and the VFR at 24 weeks ( $P = 0.073$ ) was not (Table 4).

### **Survival in patients without early recurrence**

A subgroup analysis of 69 patients without recurrence at 6 months after resection was performed (Fig. 5). The higher group at the SMR at 24 weeks after resection was related to longer OS than the lower group (61.9 vs. 48.0 months) although this was not statistically significant ( $P = 0.07$ ).

## Discussion

Several studies have suggested that sarcopenia at the time of diagnosis or preoperative weight loss may be associated with reduced overall survival in all stages of PC [8,17,21]. It may be natural for sarcopenia to reflect the nutritional status at the time of diagnosis [22], which can influence survival. At the time of diagnosis, sarcopenia cannot be manipulated; however, after resection, it can be controlled by cancer rehabilitation therapies, including nutritional support or medication [23]. Moreover, according to recent experimental models, an inhibition of the cachexia-related cytokine pathway may dramatically increase the lifespan by inhibiting cancer-induced weight loss although indicating minimal antitumor effects [24]. Therefore, it is worth investigating the serial changes in body composition that may influence survival in patients with resected PC.

In our research, there was no difference in the OS with respect to the SMM before resection. However, it was found that a restoration of SMM at 24 weeks after resection is associated with favorable outcomes in patients with resected PC (39 vs. 20 months,  $P = 0.008$ ). This may be because patients with depletion of SMM present higher chemotherapy-related toxicity and poor prognosis, whereas those with larger amounts of SMM may show fewer toxicities and better outcomes [25]. To the best of our knowledge, this is the first study analyzing the relationship between body composition trajectory and survival in patients with PC after resection. The data presented in this study could suggest that the preservation of muscle mass impacts survival and postoperative rehabilitation improves survival in

patients with resected PC.

Patients with PC frequently experience recurrence even after complete resection followed by adjuvant treatment. To minimize the impact on sarcopenia by early recurrence, a subgroup analysis was performed, with the exception of early recurrence. The OS of patients with preserved SMM tended to be better. Currently, it is unable to be provided an exact as to why the restoration of muscle mass was a more important factor with respect to survival than preoperative SMM in patients with resected PC, which is similar to the findings of a previous study that included patients with unresectable colorectal cancer [26].

A recent study reported that accelerated SMM and VFM losses were associated with reduced survival in patients with advanced PC [27]. In our study, the univariate analysis showed that the VFR and OS were related ( $P = 0.023$ ). However, this was not significant in the multivariate Cox regression analysis ( $P = 0.073$ ). Therefore, this result suggests that the changes in the SMM over time have a greater impact on survival than the VFR.

Recently, there have been some studies asserting that physical activity and exercise may have a positive effect on the management of cancer cachexia by improving health-related quality of life, physical performance [28, 29]. In a randomized, controlled trial of 231 patients with cancer, an 8-week physical exercise program showed significant improvement in patients' physical performance [29]. Although there is insufficient evidence of its effectiveness and practicality to date, exercise appears to be beneficial to patients with or at risk of cancer cachexia



[30, 31]. Accordingly, an exercise program for patients with cancer should be developed. Based on the result of our study, we believe that exercise from 12 to 24 weeks after PC resection is important for production of SMM; hence, it may be necessary to develop an exercise program during this post-resection period.

It was hypothesized that PPPD or PD may induce a greater reduction in the SMM or VFM than DP due to the altered anatomy of the digestive tract. However, statistical analysis showed that a surgical method had no impact on the change in body composition. This suggests that PC itself is a more important factor influencing the body composition changes than the operation method or the remaining volume of the pancreas.

This study has some limitations. It was conducted at a single-institution, retrospective design with a small sample size. However, the strength of this study may be that we used an objective index of CT to measure the serial body composition changes with a duration of up to 6 months after resection.

In conclusion, this study suggests that the restoration of SMM at 24 weeks after surgery is an independent prognostic factor for survival in patients with resected PC. It is proposed that a development of therapeutic strategies focused on improving the OS is important for the rehabilitation and restoration of muscle mass in patients with resected PC.

## **Conclusion**

We found that the restoration of muscle mass at 24 weeks after resection is an independent prognostic factor for survival in patients with resected PC. The importance of this finding is that it can be helpful in the development of a therapeutic strategy for the rehabilitation of patients with PC after resection.

## References

1. Siegel R, Naishadham D, Jemal A. Cancer statistics, 2012. *CA Cancer Clin* 2012; 62: 10-29
2. Oettle H, Post S, Neuhaus P, Gellert K, Langrehr J, Ridwelski K, Schramm H, Fahlke J, Zuelke C, Burkart C, Guberlet K, Kettner E, Schmalenberg H, Weigang-Koehler K, Bechstein W, Niedergethmann M, Schmidt-Wolf I, Lars Roll, Doerken B, Riess H. Adjuvant chemotherapy with gemcitabine vs observation in patients undergoing curative-intent resection of pancreatic cancer: a randomized controlled trial. *JAMA* 2007;297: 267–77
3. Ueno H, Kosuge T, Matsuyama Y, Yamamoto J, Nakao A, Egawa S, Doi R, Monden M, Hatori T, Tanaka M, Shimada M, Kanemitsu K. A randomized phase III trial comparing gemcitabine with surgery-only in patients with resected pancreatic cancer: Japanese Study Group of Adjuvant Therapy for Pancreatic Cancer. *Br J Cancer* 2009;101: 908–15
4. Schnelldorfer T, Ware AL, Sarr MG, Smyrk TC, Zhang L, Qin R, Gullerud RE, Donohue JH, Nagorney DM, Farnell MB. Long-term survival after pancreatoduodenectomy for pancreatic adenocarcinoma: is cure possible? *Ann Surg* 2018;247: 456–62
5. Ferrone CR, Brennan MF, Gonen M, Coit DG, Fong Y, Chung S, Tang L, Klimstra D, Allen PJ. Pancreatic adenocarcinoma: the actual 5-year survivors. *J Gastrointest Surg* 2018;12: 701–6

6. Tan BH, Birdsell LA, Martin L, Baracos VE, Fearon KC. Sarcopenia in an overweight or obese patient is an adverse prognostic factor in pancreatic cancer. *Clin Cancer Res* 2009;15(22): 6973-9
7. Lim JE, Chien MW, Earle CC. Prognostic factors following curative resection for pancreatic adenocarcinoma a population-based, linked database analysis of 396 patients. *Ann Surg.* 2003;237(1): 74-85
8. Rosenberg I. Summary comments; epidemiological and methodological problems in determining nutritional status of older persons. *Am J Clin Nutr.* 1989;50: 1231-3
9. Roubenoff R. Origins and clinical relevance of sarcopenia. *Can J Appl Physiol* 2001;26(1):78-89
10. Evans WJ. What is sarcopenia? *J Gerontol A Biol Sci Med Sci* 1995;50. Spec:5-8
11. Cruz-Jentoft AJ, Baeyens JP, Bauer JM, Boirie Y, Cederholm T, Landi F, Martin FC, Michel JP, Rolland Y, Schneider SM, Topinková E, Vandewoude M, Zamboni M. European Working Group on Sarcopenia in Older People. Sarcopenia: European consensus on definition and diagnosis: Report of the European working group on sarconia in older people. *Age Ageing* 2010;39: 412-23
12. Christensen JF, Jones LW, Andersen JL, Dagaard G, Rorth M, Hojman P. Muscle dysfunction in cancer patients. *Ann Oncol* 2014;25: 947-58
13. Valter Santilli, Andrea Bernetti, Massimiliano Mangone, Marco Paoloni.

Clinical definition of sarcopenia. *Clin Cases Miner Bone Metab* 2014;11(3):177-180

14. Stene GB, Helbostad JL, Amundsen T, Sørhaug S, Hjelde H, Kaasa S, Grønberg BH. Changes in skeletal muscle mass during palliative chemotherapy in patients with advanced lung cancer. *Acta Oncol* 2015;54: 340-8

15. Elliott JA, Doyle SL, Murphy CF, King S, Guinan EM, Beddy P, Ravi N, Reynolds JV. Sarcopenia: prevalence, and impact on operative and oncologic outcomes in the multimodal management of locally advanced esophageal cancer. *Ann Surg* 2017;266: 822-30

16. Malietzis G, Currie AC, Johns N, Fearon KC, Darzi A, Kennedy RH, Athanasiou T, Jenkins JT. Skeletal muscle changes after elective colorectal cancer resection: a longitudinal study. *Ann Surg Oncol* 2016;23: 2539-47

17. Akahori T, Sho M, Kinoshita S, Nagai M, Nishiwada S, Tanaka T, Tamamoto T, Ohbayashi C, Hasegawa M, Kichikawa K, Nakajima Y. Prognostic significance of muscle attenuation in pancreatic cancer patients treated with neoadjuvant chemoradiotherapy. *World J Surg* 2015;39: 2975–82

18. Cooper AB, Slack R, Fogelman D, Holmes HM, Petzel M, Parker N, Balachandran A, Garg N, Ngo-Huang A, Varadhachary G, Evans DB, Lee JE, Aloia T, Conrad C, Vauthey JN, Fleming JB, Katz MH. Characterization of anthropometric changes that occur during neoadjuvant therapy for potentially resectable pancreatic cancer. *Ann Surg Oncol* 2015; 22: 2416–23

19. Choi Y, Oh DY, Kim TY, Lee KH, Han SW, Im SA, Kim TY, Bang TY. Skeletal muscle depletion predicts the prognosis of patients with advanced pancreatic cancer undergoing palliative chemotherapy, independent of body mass index. *PLoS ONE* 2015;10(10): e0139749.
20. Mintziras I, Miligkos M, Wächter S, Manoharan J, Maurer E, Bartsch DK. Sarcopenia and sarcopenic obesity are significantly associated with poorer overall survival in patients with pancreatic cancer: Systematic review and meta-analysis. *International Journal of Surgery* 2018;59: 19–26
21. Dalal S, Hui D, Bidaut L, Lem K, Del Fabbro E, Crane C, Reyes-Gibby CC, Bedi D, Bruera E. Relationships among body mass index, longitudinal body composition alterations, and survival in patients with locally advanced pancreatic cancer receiving chemoradiation: a pilot study. *J Pain Symptom Manage* 2012;44: 181-91
22. Delitto D, Judge SM, George TJ Jr, Sarosi GA, Thomas RM, Behrns KE, Hughes SJ, Judge AR, Trevino JG. A clinically applicable muscular index predicts long-term survival in resectable pancreatic cancer. *Surgery* 2017;161: 930-8
23. Meza-Junco J, Montano-Loza AJ, Baracos VE, Prado CM, Bain VG, Beaumont C, Esfandiari N, Lieffers JR, Sawyer MB. Sarcopenia as a prognostic index of nutritional status in concurrent cirrhosis and hepatocellular carcinoma. *J Clin Gastroenterol* 2013;47: 861-70
24. Wakabayashi H, Uwano R. Rehabilitation nutrition for possible sarcopenic

dysphagia after lung cancer surgery: a case report. *Am J Phys Med Rehabil* 2016;95(6): e84-9

25. Johnston AJ, Murphy KT, Jenkinson L, Laine D, Emmrich K, Faou P, Weston R, Jayatileke KM, Schloegel J, Talbo G, Casey JL, Levina V, Wong WW, Dillon H, Sahay T, Hoogenraad J, Anderton H, Hall C, Schneider P, Tanzer M, Foley M, Scott AM, Gregorevic P, Liu SY, Burkly LC, Lynch GS, Silke J, Hoogenraad NJ. Targeting of Fn14 prevents cancer-induced cachexia and prolongs survival. *Cell* 2015;162: 1365–78

26. Jung HW, Kim JW, Kim JY, Kim SW, Yang HK, Lee JW, Lee KW, Kim DW, Kang SB, Kim CH, Kim JH. Effect of muscle mass on toxicity and survival in patients with colon cancer undergoing adjuvant chemotherapy. *Support Care Cancer* 2015;23: 687-94

27. Miyamoto Y, Baba Y, Sakamoto Y, Ohuchi M, Tokunaga R, Kurashige J, Hiyoshi Y, Iwagami S, Yoshida N, Watanabe M, Baba H. Negative impact of skeletal muscle loss after systemic chemotherapy in patients with unresectable colorectal cancer. *PLoS One* 2015;10: e0129742.

28. Di Sebastiano KM, Yang L, Zbuk K, Wong RK, Chow T, Koff D, Moran GR, Mourtzakis M. Accelerated muscle and adipose tissue loss may predict survival in pancreatic cancer patients: the relationship with diabetes and anaemia. *Br J Nutr*. 2013;109: 302–12


29. Mishra SI, Scherer RW, Snyder C, Geigle P, Gotay C. The effectiveness of

exercise interventions for improving health-related quality of life from diagnosis through active cancer treatment. *Oncol Nurs Forum* 2015;42: E33-E53

30. Oldervoll LM, Loge JH, Lydersen S, Paltiel H, Asp MB, Nygaard UV, Oredalen E, Frantzen TL, Lesteberg I, Amundsen L, Hjermstad MJ, Haugen DF, Paulsen Ø, Kaasa S. Physical exercise for cancer patients with advanced disease: a randomized controlled trial. *Oncologist* 2011;16: 1649-57


31. Grande AJ, Silva V, Maddocks M. Exercise for cancer cachexia in adults: Executive summary of a Cochrane Collaboration systematic review. *J Cachexia Sarcopenia Muscle* 2015;6: 208-110






**Figure 1. Survival according to the body mass index (BMI), skeletal muscle mass (SMM), and visceral fat mass (VFM) before resection.**

The Kaplan–Meier analysis found no significant difference in the overall survival (OS) according to the BMI, SMM, and VFM before resection. The orange and blue lines indicate the higher and lower groups, respectively. (A) BMI before resection ( $P = 0.311$ ), (B) SMM before resection ( $P = 0.234$ ), and (C) VFM before resection ( $P = 0.667$ ).




**Figure 2. Survival according to the change in the skeletal muscle mass ratio (SMR).**

When we analyzed the SMR at each time point, there was no significant difference in the median overall survival (OS) between the higher and lower groups at 4 ( $P = 0.488$ ) and 12 ( $P = 0.397$ ) weeks after resection (A, B). However, the higher group showed a longer median OS than the lower group at 24 weeks (39 vs. 20 months,  $P = 0.008$ ) (C).




**Figure 3. Survival according to the change in the visceral fat mass ratio (VFR).**

When we analyzed the VFR, the overall survival (OS) did not differ significantly between the higher and lower groups at 4 ( $P = 0.732$ ) and 12 ( $P = 0.060$ ) weeks after resection (A, B). However, the OS was longer in the higher visceral fat group at 24 weeks (35 vs. 22 months,  $P = 0.023$ ) (C).



**Figure 4. Survival according to the change in the body composition ratio in both gender groups at 24 weeks after resection.**

The patients were divided into the male group (A) and female group (B), and the effect of the restoration of skeletal muscle mass (SMM) at 24 weeks after surgery on the overall survival (OS) was analyzed using the Kaplan–Meier method. In this Kaplan–Meier analysis, the SMM and OS were not statistically significant in the male group ( $P = 0.213$ ) but were significant in the female group ( $P = 0.002$ ).



**Figure 5. Subgroup analysis: except for the early recurrence group.**

Overall survival (OS) according to the change in the skeletal muscle mass ratio (SMR) at 24 weeks after surgery. In the lower group (blue line), the SMR at 24 weeks after resection was related to shorter overall survival than that in the higher group (red line), but this was not statistically significant ( $P = 0.07$ ).

**Table 1. Patient demographics and clinical characteristics**

Variables	<i>n</i> = 89
Age (range), years	63 (27–84)
Sex	
Male (%)	55 (61.8%)
Female (%)	34 (38.2%)
BMI* (range) (kg/m <sup>2</sup> )	23.0 (17.0–35.8)
Diabetes mellitus	38 (42.7%)
ASA grade†	
I	25 (28.1%)
II	54 (60.7%)
III	10 (11.2%)
Tumor location	
Head	57 (64.0%)
Body	15 (16.9%)
Tail	17 (19.1%)
Differentiation of tumor	
Well differentiated	7 (7.4%)
Moderately differentiated	71 (77.7%)
Poorly differentiated	6 (7.4%)
Undifferentiated	5 (7.4%)
Postoperative TNM stage	
IA	10 (11.2%)
IB	29 (32.6%)
IIA	9 (10.1%)
IIB	34 (38.2%)
III	7 (7.9%)
Type of resection	
Standard pancreaticoduodenectomy	16 (18.0%)
Pylorus-preserved pancreaticoduodenectomy	46 (51.7%)
Distal pancreatectomy	27 (30.3%)
Surgical margin state	
R0	67 (75.3%)
R1	22 (24.7%)
Adjuvant chemotherapy (≥4 cycles)	57 (64.0%)

\* BMI, body mass index; † ASA grade, American Society of Anesthesiologists grade

**Table 2. Change in body composition parameters after resection of pancreatic cancer (mean, standard deviation)**

Variables	Before resection	4 weeks after resection	12 weeks after resection	24 weeks after resection
<b>Total</b>				
BMI	23.0 (19.0–26.0)	22.6 (18.1–27.1)	21.2 (17.0–25.4)	20.6 (15.8–25.4)
Skeletal muscle*, cm <sup>2</sup>	118.7 (93.4–144.1)	121.5 (98.7–144.2)	110.2 (85.5–135.0)	109.9 (86.5–133.3)
Skeletal muscle index†	44.7 (37.7–51.7)	45.9 (39.5–52.2)	41.5 (34.3–48.6)	41.5 (34.3–48.6)
Visceral fat‡, cm <sup>2</sup>	94.6 (46.8–142.4)	86.6 (41.4–131.8)	64.9 (30.4–99.4)	62.3 (27.5–97.1)
Skeletal muscle ratio	1.000	1.031 (0.959–1.104)	0.931 (0.858–1.004)	0.931 (0.838–1.023)
Visceral fat ratio	1.000	0.943 (0.721–1.165)	0.767 (0.331–1.203)	0.758 (0.288–1.228)
<b>Males</b>				
BMI	22.5 (19.7–25.3)	21.8 (16.7–26.9)	21.1 (17.3–24.9)	20.8 (17.0–24.6)
Skeletal muscle, cm <sup>2</sup>	132.2 (111.3–153.2)	132.2 (111.9–152.5)	123.0 (101.9–144.1)	120.9 (99.7–142.0)
Skeletal muscle index	47.2 (40.5–53.9)	47.2 (40.8–53.7)	43.9 (37.2–50.6)	43.2 (35.8–50.6)
Visceral fat, cm <sup>2</sup>	100.5 (49.3–151.6)	90.6 (43.7–137.5)	68.6 (31.0–106.3)	65.9 (28.3–103.6)
Skeletal muscle ratio	1.000	1.002 (0.949–1.055)	0.934 (0.866–1.002)	0.916 (0.825–1.007)
Visceral fat ratio	1.000	0.925 (0.722–1.128)	0.749 (0.309–1.190)	0.735 (0.276–1.194)
<b>Females</b>				
BMI	23.7 (20.5–26.9)	23.7 (20.6–26.8)	21.4 (16.6–26.2)	20.4 (14.2–26.6)
Skeletal muscle, cm <sup>2</sup>	96.9 (82.8–111.0)	104.1 (89.9–118.3)	89.6 (75.7–103.4)	92.2 (77.8–106.6)
Skeletal muscle index	40.6 (35.1–46.1)	43.6 (38.1–49.2)	37.5 (32.0–43.1)	38.7 (32.9–44.4)
Visceral fat, cm <sup>2</sup>	85.1 (44.3–125.9)	80.1 (37.9–122.4)	58.9 (30.9–86.9)	56.5 (27.3–85.8)
Skeletal muscle ratio	1.000	1.078 (1.002–1.154)	0.926 (0.845–1.008)	0.954 (0.862–1.046)
Visceral fat ratio	1.000	0.971 (0.721–1.222)	0.795 (0.361–1.228)	0.795 (0.304–1.286)

\* Skeletal muscle area at the third lumbar level; † Skeletal muscle index: skeletal muscle area/the square of the height,  $\text{cm}^2/\text{m}^2$ ; §

Visceral fat area at the third lumbar level



**Table 3. Characteristics of the higher and lower groups (at 24 weeks after resection)**

Variables	Higher group, n = 46	Lower group, n = 43	<i>P</i>
Median age (range), years	62.5 (27–77)	64 (35–84)	0.761
Sex, no (%)			0.400
Male	26 (56.5%)	29 (67.4%)	
Female	20 (43.5%)	14 (32.6%)	
BMI* (range) (kg/m <sup>2</sup> )	21.5 (16.9–27.3)	20.6 (15.4–30.9)	0.238
Diabetes mellitus	24 (52.2%)	14 (32.6%)	0.098
ASA grade†			0.091
I	15 (32.6%)	10 (23.3%)	
II	29 (63.0%)	25 (58.1%)	
III	2 (4.4%)	8 (18.6%)	
Tumor location			0.775
Head	29 (63.0%)	28 (65.1%)	
Body	7 (15.22%)	8 (18.6%)	
Tail	10 (21.74%)	7 (16.3%)	
Differentiation of tumor			0.374
Well	5 (10.9%)	2 (4.7%)	
Moderately	34 (73.9%)	37 (86.1%)	
Poorly	3 (6.5%)	3 (7.0%)	
Undifferentiated	4 (8.7%)	1 (2.3%)	
Type of resection			0.423
Standard PD	6 (13.0%)	10 (23.3%)	
PPPD	26 (56.5%)	20 (46.5%)	
DP	14 (30.4%)	13 (30.4%)	
Surgical margin			0.017
R0	40 (87.0%)	27 (62.8%)	
R1	6 (13.0%)	16 (37.2%)	
Adjuvant chemotherapy	38 (82.6%)	37 (86.0%)	0.878

\* BMI, body mass index at the time of diagnosis; † ASA grade, American Society of

Anesthesiologists grade; ‡ PD, pancreaticoduodenectomy

**Table 4. Prognostic factors for overall survival in the univariate and multivariate analyses at 6 months after resection of pancreatic cancer**

Factors	OS (month)	Univariate analysis		Multivariate analysis	
		HR (95% CI)	<i>P</i> value	HR (95% CI)	<i>P</i> value
Gender (male)	26.5	1.35 (0.78–2.33)	0.289	1.13 (0.62–2.08)	0.683
Age (≥65)	27.6	1.16 (0.69–1.96)	0.585	1.04 (0.30–3.60)	0.947
Adjuvant chemotherapy	29.5	0.54 (0.28–1.00)	0.050	0.58 (0.29–1.12)	0.105
Low VFR*	35.8	0.54 (0.32–0.92)	0.023	0.59 (0.33–1.05)	0.073
Low SMR†	35.8	0.49 (0.29–0.83)	0.008	0.52 (0.30–0.92)	0.023

\* Low VFR, patients whose ratio of visceral fat of the third lumbar area at 24 weeks point after resection to the visceral fat at the third lumbar area on pre-resection point is lower than the median value

† Low SMR, patients whose ratio of skeletal muscle of the third lumbar area at 24 weeks point after resection to skeletal muscle of the third lumbar area on pre-resection point is lower than the median value

## 췌장암으로 절제를 받은 환자에서

### 수술 후 근육량 보존이 생존에 미치는 영향

최근의 여러 연구에서 췌장암 환자에 있어, 근감소증이 예후를 예측할 수 있는 인자임이 밝혀지고 있다. 그러나 대부분의 이러한 연구들은 진단 당시의 근감소증을 기준으로 하기에, 시간에 따른 근감소증의 변화와 예후와의 상관 관계를 설명하기에는 부족한 면이 있다. 이에 본 연구에서 저자들은 췌장암으로 절제를 받은 환자들의 체성분의 변화와 예후를 비교 분석하여 시간에 따른 체성분의 변화가 예후에 미치는 영향을 평가하고자 하였다.

2006년부터 2015년까지 췌장암으로 절제를 받은 89명의 환자들을 대상으로 하였다. 이들은 근치적 목적으로 수술을 받았으며, 수술 전, 수술 후 4주, 수술 후 12주, 수술 후 24주째에 복부 전산화 단층 촬영을 한 환자들이다. 저자들은 이 복부 전산화 단층 촬영 영상을 sliceOmatic V5.0 프로그램 (Tomovision)을 이용하여 세번째 요추 부위의 근육 및 내장 지방의 면적을 측정 한 후 각 시점(4/12/24주)의 체성분을 수술 전 체성분으로 나누었다. 체성분 변화의 비를 구한 후 각 시점의 중앙값을

기준으로 체성분 변화의 비가 높은 집단과 낮은 집단으로 나눈 후 두 집단간의 생존율을 로그순위법을 이용하여 비교하였다.

환자들의 나이의 중앙값은 63세 (27-84) 였으며, 체질량지수의 중앙값은  $23.0 \text{ kg/m}^2$  (17.0-35.8) 이었다. 근육 변화의 비를 살펴봤을 때 4주와 12주에는 두 집단간의 생존율의 차이가 통계적으로 유의하지 않았다 (4주,  $P = 0.488$ ; 12주,  $P = 0.397$ ). 그러나 24주에는 근육량의 비가 높은 집단이 낮은 집단 보다 높은 생존율을 보였다 (39 개월 vs. 20 개월;  $P = 0.008$ ). 유사하게 내장 지방 변화의 비를 살펴봤을 때 4주와 12주에서는 두 집단간의 생존율의 차이가 통계적으로 유의하지 않았다 (4주,  $P = 0.732$ ; 12주,  $P = 0.060$ ). 그러나 24주에서는 내장 지방량의 비가 높은 집단이 낮은 집단 보다 높은 생존율을 보였다. (35 개월 vs. 22개월;  $P = 0.023$ ). 다변량 콕스 회귀 분석에서는 24주의 근육 면적의 비가 생존율과 유의하게 관련이 있었다. 6개월 이내에 재발한 환자들을 제외한 하위 집단 분석에서는 24주의 근육 면적의 비가 관계가 있는 것으로 나타났으나, 통계적으로는 유의하지 않았다.

이에 24주의 근육량의 보존이 췌장암으로 절제를 받은 환자들에 있어 독립적인 예후 인자일 가능성이 있으며, 이에 따른 치료 전략의 수립이 환자의 예후에 도움이 될 것이다.

.....  
주요어: 근감소증, 근육량, 내장 지방량, 췌장암, 체성분 변화

학 번: 2017-23421